George Ayoub

George Ayoub is an experienced professional in the biomedical and therapeutic sectors, currently serving as a Member of the Board of Directors at Nammi Therapeutics, Inc. since January 2021. Additionally, George is the Managing Partner at Ayoub Holding since January 2013 and has been a Board member of the Southern California Biomedical Council since 2001. Previously, George co-founded and served as CEO of Qwixel Therapeutics, LLC, from December 2016 to January 2022, where the focus was on developing innovative therapies for Multiple Myeloma. George also held the position of Strategic Advisor at Thermo Fisher Scientific during the integration of One Lambda, Inc. and served as President/CEO of One Lambda, Inc. for nearly three decades. Early in the career, George worked as a researcher at UCLA Tissue Typing, contributing to advancements in HLA typing methodologies and authoring several scientific publications. George holds a degree in Biochemistry from UCLA and an MBA in Marketing/Management from Pepperdine University.